NCT07139639View on ClinicalTrials.gov

Evidence-Based Evaluation of Classic Herb Pair (Chuanxiong Rhizoma and Salviae Miltiorrhizae) for Preventing Recurrence of Diabetic Lower Extremity Arterial Disease

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

November 1, 2027

Study Completion Date

December 1, 2028

Conditions
Diabetic Lower Extremity Arterial Disease
Interventions
DRUG

Guanxinning Tablets

"Guanxinning Tablets~* Manufacturer: Zhengda Qingchunbao Pharmaceutical Co., Ltd.~* NMPA Approval No. Z20150028~* Administration: 4 tablets orally, three times daily for 6 months"

DRUG

Matching Placebo for Guanxinning

"Matching Placebo for Guanxinning Tablets~* Manufacturer: Zhengda Qingchunbao Pharmaceutical Co., Ltd.~* Drug Product Certificate of Analysis Approval No.YF-R-C037A-2024104-A~* Administration: 4 tablets orally, three times daily for 6 months"

All Listed Sponsors
collaborator

Beijing Shijitan Hospital, Capital Medical University

OTHER

collaborator

Peking University Third Hospital

OTHER

collaborator

Dongzhimen Hospital, Beijing

OTHER

collaborator

Xuanwu Hospital, Beijing

OTHER

collaborator

The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine

OTHER

collaborator

Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology

OTHER

lead

Zheng Liu

OTHER